Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
Open Access
- 11 July 2023
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (4) , 768-779
Abstract
Fluoropyrimidine (FP) chemotherapy is associated with severe, life‐threatening toxicities, particularly among patients who carry deleterious germline variants in the DPYD gene. Pretreatment DPYD testing is standard of care throughout most of Europe; however, it has not been recommended in clinical practice guidelines in the United States. Due to increased risk of severe toxicity, a Citizen's Petition asked the US Food and Drug Administration (FDA) to update language in FP drug labels to recommend DPYD testing as part of a boxed warning and recommend FP dose reduction in patients carrying deleterious germline variants. In response, the FDA updated the capecitabine package insert to inform patients about the toxicity risk and test availability and consider DPYD testing. However, the FDA did not include a testing recommendation or requirement, or a boxed warning. Additionally, the FDA did not recommend FP dose adjustment in DPYD variant carriers. This review provides a critical assessment of the DPYD‐FP pharmacogenetic association using the FDA's previously published Pharmacogenetic Pyramid, demonstrating that the evidence is compelling for recommending DPYD testing prior to FP treatment. Additionally, the FDA's stated concerns about recommending DPYD testing and DPYD‐guided FP dose adjustment are addressed and discussed in the context of the FDA's other genetic testing and dose adjustment recommendations. We call on the FDA to follow our European counterparts in recommending DPYD testing and genotype‐based dose adjustment to ensure patients with cancer receive safe and effective FP chemotherapy.Keywords
This publication has 56 references indexed in Scilit:
- DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)JNCI: Journal of the National Cancer Institute, 2014
- The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparencyNucleic Acids Research, 2012
- Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypesThe Pharmacogenomics Journal, 2012
- Allopurinol Pharmacogenetics: Assessment of Potential Clinical UsefulnessPharmacogenomics, 2011
- Lethal outcome of 5‐fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutationBritish Journal of Clinical Pharmacology, 2010
- Pharmacogenetics in Medicine: Barriers, Critical Factors and a Framework for DialoguePersonalized Medicine, 2009
- Potential Regional Differences for the Tolerability Profiles of FluoropyrimidinesJournal of Clinical Oncology, 2008
- Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with CaucasiansClinical Cancer Research, 2006
- 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a caseJournal of Clinical Pathology, 2005
- Capecitabine: A reviewClinical Therapeutics, 2005